Achmea Investment Management B.V. Has $1.31 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Achmea Investment Management B.V. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 90.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,841 shares of the biopharmaceutical company’s stock after selling 17,567 shares during the period. Achmea Investment Management B.V.’s holdings in Regeneron Pharmaceuticals were worth $1,311,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in REGN. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $26,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Private Wealth Management Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $39,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several research analyst reports. Bernstein Bank decreased their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Trading Down 2.0 %

NASDAQ REGN opened at $666.87 on Friday. The firm has a market cap of $72.91 billion, a P/E ratio of 17.42, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock’s 50-day moving average is $694.91 and its 200-day moving average is $833.75. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.